MagForce AG
Max-Planck-Straße 3, 12489 Berlin
+49 30 308380-0
+49 30 308380-99
Management
Dr. Ben J. Lipps
Contact
Denise Scharke
Focus
MagForce AG is a pioneer in the area of nanotechnology-based cancer treatment. It is the first company in the world to receive European approval for a medical product using nanoparticles. In Germany, this innovative therapy is available to patients at the NanoTherm™ therapy centers at the Charité-Universitätsmedizin hospital in Berlin, and the university hospitals in Münster and Kiel. Additional therapy centers in Germany are planned.
News
MagForce AG Successfully Completes Private Placement of New Shares
Medical device company increases share capital with gross proceeds of approx. EUR 4.7 million
Medical device company increases share capital with gross proceeds of approx. EUR 4.7 million
MagForce AG and affiliated European clinics support World Brain Tumor Day on 8 June
At virtual events, patients receive advice on treatment approaches with NanoTherm Therapy
At virtual events, patients receive advice on treatment approaches with NanoTherm Therapy
The aim to provide brain tumor patients with the best care possible
MagForce hosts practice-oriented application training for the use of the NanoTherm therapy system in treating brain tumors and intends to increase the ...
MagForce hosts practice-oriented application training for the use of the NanoTherm therapy system in treating brain tumors and intends to increase the ...
MagForce will focus on establishing cancer treatment with NanoTherm™ therapy
Biotech company publishes financial results and operative highlights
Biotech company publishes financial results and operative highlights
